Evidence map›Paper›PMID 38858747›Full record

ArticleBMC complementary medicine and therapies2024

Ge-Gen-Qin-Lian decoction alleviates the symptoms of type 2 diabetes mellitus with inflammatory bowel disease via regulating the AGE-RAGE pathway.

Zhipeng Li, Ziwei Zhao, Shujuan Chen, Xiaojuan Wang, Dongsheng Wang, Xiaoli Nie, Ye Yao

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhipeng Li *Department of Nephrology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, No. 13, Shi Liu Gang Road, Haizhu District, Guangzhou, Guangdong Province, 510315, China.
Ziwei Zhao *Department of Nephrology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, No. 13, Shi Liu Gang Road, Haizhu District, Guangzhou, Guangdong Province, 510315, China.
Shujuan ChenDepartment of Nephrology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, No. 13, Shi Liu Gang Road, Haizhu District, Guangzhou, Guangdong Province, 510315, China.
Xiaojuan WangDepartment of Nephrology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, No. 13, Shi Liu Gang Road, Haizhu District, Guangzhou, Guangdong Province, 510315, China.
Dongsheng WangInstitute of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xiaoli NieDepartment of Nephrology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, No. 13, Shi Liu Gang Road, Haizhu District, Guangzhou, Guangdong Province, 510315, China. nxl117@smu.edu.cn.
Ye YaoDepartment of Nephrology, Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, No. 13, Shi Liu Gang Road, Haizhu District, Guangzhou, Guangdong Province, 510315, China. yaoye0719@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to explore the mechanism of Ge-Gen-Qin-Lian decoction (GGQLD) in the alleviation of symptoms of type 2 diabetes mellitus (T2DM) with inflammatory bowel disease (IBD) by network pharmacology and experimental validation.

methodsThe active components and targets of GGQLD were identified from the TCMSP database. The potential therapeutic targets of T2DM and IBD were identified from the GEO database and 4 online disease target databases. The PPI network and KEGG/GO analyses were performed with the common targets among GGQLD, T2DM and IBD. Molecular docking was carried out between the core compounds and hub targets. To verify the above results, UHPLC-MS technology was used to identify the chemical compounds in GGQLD, and a T2DM with IBD rat model was used to explore the mechanism by which GGQLD treats T2DM with IBD.

resultsTotally, 70 potential therapeutic targets were identified among GGQLD, T2DM and IBD. Ten hub genes were selected from the PPI network. KEGG analysis revealed that GGQLD is tightly involved in the AGE-RAGE signaling pathway. Berberine, baicalein, wogonin, and quercitrin are the main active compounds of GGQLD. Animal experiments showed that GGQLD could decrease blood glucose and alleviate intestinal inflammation. Notably, the concentrations of AGEs, the expression of RAGE, c-JUN and NF-κB and the expression of inflammatory cytokines were decreased by GGQLD.

conclusionsOur study initially demonstrated that GGQLD has favorable anti-hyperglycemic and anti-intestinal inflammation effects in a T2DM with IBD rat model, and the AGE-RAGE pathway plays a vital role in this process.

Indexed as

Diabetes Mellitus, Type 2Drugs, Chinese HerbalInflammatory Bowel DiseasesAnimalsDiabetes Mellitus, ExperimentalDisease Models, AnimalMaleMolecular Docking SimulationNetwork PharmacologyRatsRats, Sprague-DawleyReceptor for Advanced Glycation End ProductsSignal TransductionDrugs, Chinese HerbalgegenqinlianReceptor for Advanced Glycation End ProductsAGE-RAGE pathwayGe-Gen-Qin-Lian decoctionInflammatory bowel diseaseNetwork pharmacologyType 2 diabetes mellitus

Identifiers

PMID38858747
PMCPMC11163797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.